A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PART I Company Overview Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology. The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF (as defined in Part I, Item I Business, Company Overview, Ivonescimab) compound into a single molecule. On December 5, 2022, the Company entered into the License Agreement with Akeso, Inc.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | - | - |
| Net Income | -1.1B | -221M | -615M | -79M | -89M | -53M |
| EPS | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 | $-0.76 |
| Free Cash Flow | -324M | -142M | -77M | -42M | -73M | -49M |
| ROIC | 0.0% | -56.9% | -237.3% | -12.7% | -106.4% | -66.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.02 | 1.37 | 4.25 | 0.03 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | 0 | -226M | -610M | -72M | -86M | -53M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -163.9% | -56.9% | -791.5% | -62.2% | -106.4% | -66.3% |
| Shares Outstanding | 775M | 714M | 621M | 702M | 698M | 69M |
Summit Therapeutics Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +17.9%.
Summit Therapeutics Inc. (SMMT) has a 5-year average return on invested capital (ROIC) of -60.6%. This is below average and may indicate limited pricing power.
Summit Therapeutics Inc. (SMMT) has a market capitalization of $16.2B. It is classified as a large-cap stock.
Summit Therapeutics Inc. (SMMT) does not currently pay a regular dividend.
Summit Therapeutics Inc. (SMMT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Summit Therapeutics Inc. (SMMT) generated $-142 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Summit Therapeutics Inc. (SMMT) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Summit Therapeutics Inc. (SMMT) reported earnings per share (EPS) of $-0.31 in its most recent fiscal year.
Summit Therapeutics Inc. (SMMT) has a return on equity (ROE) of -56.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for Summit Therapeutics Inc. (SMMT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Summit Therapeutics Inc. (SMMT) has a book value per share of $0.54, based on its most recent annual SEC filing.